Evidence map›Paper›PMID 28536844›Full record

ArticleAmino acids2017

Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.

Xiaoqin Yin, Mengzhe Wang, Hui Wang, Huaifu Deng, Tingting He, Yue Tan, Zehua Zhu, Zhanhong Wu, Shuo Hu, Zibo Li

Abstract readEvaluation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Amino acids, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Safety and tolerability ofEuropean journal of nuclear medicine and molecular imaging · 2021
    Trial
  2. Review
  3. Article
  4. Therapeutic developments in pancreatic cancer.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy.International journal of peptide research and therapeutics · 2021
    Review
  12. Review
  13. Review
  14. Article
  15. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use.European journal of nuclear medicine and molecular imaging · 2019
    Article
  16. Article
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaoqin YinPET Center of Xiangya Hospital, Central South University, Changsha, China.
Mengzhe WangDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Hui WangDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Huaifu DengDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Tingting HePET Center of Xiangya Hospital, Central South University, Changsha, China.
Yue TanPET Center of Xiangya Hospital, Central South University, Changsha, China.
Zehua ZhuPET Center of Xiangya Hospital, Central South University, Changsha, China.
Zhanhong WuDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Shuo HuPET Center of Xiangya Hospital, Central South University, Changsha, China. 402411@csu.edu.cn.
Zibo LiDepartment of Radiology and Biomedical Research Imaging Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Ziboli@med.unc.edu.

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI David Darr · 1985 to 2026
$201.5M
NCI NIH HHS P30 CA016086
6 · The paper itself

Abstract

Pancreatic cancer is one of the deadliest human malignancies and lack of effective diagnostic and therapeutic methods. Accumulating evidence suggests that the neurotensin (NT) and neurotensin receptors (NTRs) play key roles in pancreatic adenocarcinoma growth and survival. In this study, we not only evaluate the NTR1 expression in pancreatic cancer patient samples, but also explore the PET and fluorescence imaging of NTR1 expression in pancreatic cancer animal models. The NTR1 expression was evaluated by immunohistochemistry staining in clinical patient tissue samples with pancreatic ductal adenocarcinoma, insulinoma, and pancreatitis. The results showed 79.4% positive rate of NRT1 expression in pancreatic ductal adenocarcinoma, compared with 33.3 and 22.7% in insulinoma and pancreatitis samples, respectively. High NTR1 gene expression was also found in Panc-1 cells and confirmed by cell immunofluorescence.

Indexed as

AdenocarcinomaAnimalsCarcinoma, Pancreatic DuctalHumansIndolesInsulinomaMaleMiceMice, NudeNeurotensinPancreatic NeoplasmsPancreatitisReceptors, NeurotensinTissue DistributionTumor Cells, CulturedXenograft Model Antitumor AssaysIndolesIRDye800Neurotensinneurotensin type 1 receptorReceptors, NeurotensinFluorescence imagingImaging guided surgeryNeurotensin receptorPancreatic ductal adenocarcinomaPositron emission tomography

Identifiers

PMID28536844
PMCPMC5524142

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.